Table 8.
Multivariate analysis of patient prognosis in metastatic breast cancer
| Parameters | Overall survival | ||
|---|---|---|---|
| Hazard ratio | 95% CI | P -value | |
| ER status | 0.067 | ||
| Negative versus positive | 10.42 | 0.846-128.4 | |
| PR status | 0.091 | ||
| Negative versus positive | 1.195 | 0.898-4.237 | |
| HER2 status | 0.408 | ||
| Negative versus positive | 0.436 | 0.075-2.869 | |
| Ki-67 LI | 0.002 | ||
| ≤14 versus >14 | 4.096 | 1.664-10.08 | |
| Tumor phenotypes | 0.147 | ||
| Luminal A | |||
| Luminal B | 6.697 | 0.387-116.0 | |
| HER2 | 7.286 | 0.348-152.4 | |
| TNBC | 0.433 | 0.055-3.387 | |
| CAIX | 0.189 | ||
| Negative versus positive | 1.690 | 0.773-3.695 | |
| PSPH | 0.117 | ||
| Negative versus positive | 2.156 | 0.825-5.634 | |
| SHMT1 | 0.014 | ||
| Negative versus positive | 2.836 | 1.239-6.495 | |
| Serine/glycine type | 0.451 | ||
| No versus Yes | 0.723 | 0.311-1.679 | |
Bold represents p < 0.05.